Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Exubera in 2006?

This article was originally published in RPM Report

Executive Summary

Pfizer and Sanofi-Aventis will have to wait a little longer to launch inhaled insulin (Exubera). FDA is taking a three month extension to the review, meaning a decision should come before the end of January.

You may also be interested in...



Inhaled Insulin: Being First Isn't Necessarily Best

The early bird may get the worm, but it's the second mouse that finds the cheese. This has proven true many times in the drug industry in the past. It may prove true once again with inhaled insulin.

Inhaled Insulin: Being First Isn't Necessarily Best

The early bird may get the worm, but it's the second mouse that finds the cheese. This has proven true many times in the drug industry in the past. It may prove true once again with inhaled insulin.

Pfizer's Exubera: Breathing New Life Into Inhaled Insulin

Dragging a host of safety concerns, Exubera hardly inspired confidence when it went before an FDA advisory committee. But Pfizer proposed an aggressive risk management scheme that won it a dramatic "yes" vote. How one company addressed a drug's safety concerns head-on to win the confidence of FDA's advisors.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS079616

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel